SP1 and cancer: Correspondingly, the blockade of BRAFV600E/ERK signaling could reduce the recruitment of p-Sp1 to TERT promoter (Fig. 2e, f), indicating that p-Sp1 may be involved in ERK-induced GABPA binding in cancer cells.